Condition 1: crohn's disease. Condition 2: ulcerative colitis. Crohn's disease [regional enteritis] Ulcerative colitis
Conditions
Interventions
Intervention 1: Intervention group: Patients in the intervention group receive acupuncture treatment twice a week for eight weeks and a total of 16 sessions. Each acupuncture session lasts about 30 mi
Sponsors
Mashhad University of Medical Sciences
Eligibility
Sex/Gender
All
Age
16 Years to 70 Years
Inclusion criteria
Inclusion criteria: Patients diagnosed with Crohn's disease or ulcerative colitis who have been diagnosed for at least 6 months and are classified as mild to moderate according to the criteria of Crohn's disease activity index between 150 and 450 or simple clinical colitis activity index between 3 and 11 Consistency of drugs used in the last two months Sign informed consent
Exclusion criteria
Exclusion criteria: disease or skin lesion at the location of acupuncture points using adalimumab history of abdominal surgery in the last 6 months serious systemic disease using anticoagulant or thrombolytic drugs history of skin allergy and needle or metal allergy known psychiatric illness severe extraintestinal complications related to inflammatory bowel disease such as severe skin problems or thromboembolic problems fistula, abscess, intestinal obstruction, intestinal perforation history of acupuncture pregnancy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Crohn's disease activity index. Timepoint: At the beginning of the study (before the start of the intervention), 8 weeks later (ending the intervention), 16 weeks later (follow-up). Method of measurement: CDAI Scoring.;Simple clinical colitis activity index. Timepoint: At the beginning of the study (before the start of the intervention), 8 weeks later (ending the intervention), 16 weeks later (follow-up). Method of measurement: SCCAI Scoring. | — |
Secondary
| Measure | Time frame |
|---|---|
| Inflammatory bowel disease questionnaire. Timepoint: At the beginning of the study (before the start of the intervention), 8 weeks later (ending the intervention), 16 weeks later (follow-up). Method of measurement: inflammatory bowel disease questionnaire-32.;Stool calprotectin test. Timepoint: At the beginning of the study (before the start of the intervention), 8 weeks later (ending the intervention), 16 weeks later (follow-up). Method of measurement: stool sampling.;CRP test. Timepoint: At the beginning of the study (before the start of the intervention), 8 weeks later (ending the intervention), 16 weeks later (follow-up). Method of measurement: Blood sampling.;ESR test. Timepoint: At the beginning of the study (before the start of the intervention), 8 weeks later (ending the intervention), 16 weeks later (follow-up). Method of measurement: Blood sampling.;Stool Exam. Timepoint: At the beginning of the study (before the start of the intervention), 8 weeks later (ending the intervention), 16 weeks later (follow-up). Method of measurement: stool sampling.;Complete Blood Count. Timepoint: At the beginning of the study (before the start of the intervention), 8 weeks later (ending the intervention), 16 weeks later (follow-up). Method of measurement: Blood sampling. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactBehnam Bahadori
Mashhad University of Medical Sciences
Outcome results
None listed